Anonymous
Guest
Anonymous
Guest
Brennan digs in his heels and gives the finger to the largest shareholders. Wow what a fantastic team of * leaders * we have at the top guiding us through these troubled waters that they created. This is what we do at AZ, we identify and promote * leaders *.
Ref: http://www.firstwordpharma.com/node/973667
AstraZeneca CEO backs strategy following shareholder demands for change
(Ref: Bloomberg)
April 13th, 2012
By: Matthew Dennis
AstraZeneca CEO David Brennan said his position at the company remains stable despite suggestions that some shareholders are looking for a change at the drugmaker, Bloomberg reported Friday. "I’m plugged in, my role hasn’t changed a bit," Brennan remarked.
A recent report in The Financial Times said that some of the company's largest investors are lobbying to replace Brennan and other members of the board and executive team in an effort to alter the drugmaker's business strategy. "I read and hear and see lots of things, but we’re here trying to change policy, make good decisions and execute our strategy." Brennan commented.
AstraZeneca is trying to replace revenue lost when patent protection on Nexium and Seroquel expire over the next four years. However, analysts and investors have questioned whether Brennan’s stated plan to pursue smaller deals and avoid large mergers will be enough to turn around the drugmaker. "If it’s about restructuring, we can do that without a big deal. Maybe somebody sees something different, but spending more money does not have a linear increase in the number of returns you get from a research and development perspective," the CEO remarked.
Ref: http://www.firstwordpharma.com/node/973667
AstraZeneca CEO backs strategy following shareholder demands for change
(Ref: Bloomberg)
April 13th, 2012
By: Matthew Dennis
AstraZeneca CEO David Brennan said his position at the company remains stable despite suggestions that some shareholders are looking for a change at the drugmaker, Bloomberg reported Friday. "I’m plugged in, my role hasn’t changed a bit," Brennan remarked.
A recent report in The Financial Times said that some of the company's largest investors are lobbying to replace Brennan and other members of the board and executive team in an effort to alter the drugmaker's business strategy. "I read and hear and see lots of things, but we’re here trying to change policy, make good decisions and execute our strategy." Brennan commented.
AstraZeneca is trying to replace revenue lost when patent protection on Nexium and Seroquel expire over the next four years. However, analysts and investors have questioned whether Brennan’s stated plan to pursue smaller deals and avoid large mergers will be enough to turn around the drugmaker. "If it’s about restructuring, we can do that without a big deal. Maybe somebody sees something different, but spending more money does not have a linear increase in the number of returns you get from a research and development perspective," the CEO remarked.